Search Results

Your search for Joshua Spendlove, MD, and E. David Crawford, MD matches 2 pages

Showing 1 - 2

By The ASCO Post Staff / December 15 2011

Reflections from The ASCO Post

The editors gratefully acknowledge all contributors to The ASCO Post and thank the columnists who contributed to Volume 2, January–December 2011: Al B. Benson III, MD, FACP Richard Boxer, MD, FACS Carlton G. Brown, RN, PhD, AOCN Barrie R. Cassileth, PhD E. David Crawford, MD Emil J. Freireich, MD, ...

prostate cancer

By Joshua Spendlove, MD, and E. David Crawford, MD / December 15 2011

Prostate Cancer Screening Reconsidered

Prostate cancer is the most prevalent nonskin cancer in men. An estimated 16% of men are diagnosed with prostate cancer, yet only 3% of men die from it.1 Unlike other cancers, prostate cancer is associated with a prolonged lead-time, meaning it can take anywhere from 5 to 12 years to become...

Apr

Today In Oncology

Search Results

Your search for Joshua Spendlove, MD, and E. David Crawford, MD matches 2 pages

Reflections from The ASCO Post

Prostate Cancer Screening Reconsidered

Adagrasib Plus Cetuximab in KRAS G12C–Mutated Colorectal Cancer

Induction and Concurrent Vismodegib With Radiation Therapy for Locally Advanced Unresectable Basal Cell Carcinoma

FDA Approves Nogapendekin Alfa Inbakicept-pmln for BCG-Unresponsive Non–Muscle Invasive Bladder Cancer

Predicting Ovarian Cancer Relapse With Spatial Tissue Analysis

Chemohormonal Therapy for Locally Advanced Prostate Cancer